Literature DB >> 28874360

Antibiotic use in South East Asia and policies to promote appropriate use: reports from country situational analyses.

Kathleen Anne Holloway1,2,3, Anita Kotwani3, Gitanjali Batmanabane4, Monika Puri5, Klara Tisocki5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28874360      PMCID: PMC5598252          DOI: 10.1136/bmj.j2291

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
Inappropriate use of antibiotics is rampant in South East Asia1 2 3 4 5 6 and is a major contributor to antimicrobial resistance.7 8 9 However, data on antibiotic use are scant, few effective interventions to improve appropriate antibiotic use have been implemented,10 11 and implementation of policies for appropriate use of antibiotics is also poor.12 13 An analysis of secondary data on antibiotic use from 56 low and middle income countries found that countries reporting implementation of more policies also had more appropriate antibiotic use.14 15 Effective policies included having a government health department to promote rational use of medicines, a national strategy to contain antimicrobial resistance, a national drug information centre, drug and therapeutic committees in more than half of all general hospitals and provinces, and undergraduate education on standard treatment guidelines.15 An updated essential medicines list and national formularies were also associated with lower antibiotic use. Many high level forums have recommended that countries undertake routine monitoring of antibiotic use and use an integrated health systems approach to improve access to and use of medicines, including antibiotics.16 17 18 Most South East Asian countries lack the infrastructure for this, and the responsibility for medicines management is often divided between different government units with no clear accountability. Since 2010, South East Asian countries have been conducting national situational analyses on medicines management every four years,19 supported by the World Health Organization.20 This process involves rapid systematic data collection on use and availability of medicines, including antibiotics, and implementation of policies to ensure appropriate use. A multidisciplinary government team of four to eight people conducts this analysis over two weeks using a predesigned workbook tool. The process ends with a national workshop to identify priorities for action.19 We present key findings from published reports of the situational analyses done during 2010-15 19 and propose next steps to improve antibiotic management.

Methods

We reviewed all the country reports of the situational analyses published on the website of the WHO Regional Office for South-East Asia (WHO/SEARO) 19 and extracted data on antibiotic use in primary care facilities in the public sector, opinions of health workers on antibiotic use, and policies to encourage appropriate use. Box 1 summarises the methods for the country situational analyses. 19

Box 1: Summary of methods for AMR situational analysis

The workbook tool used for the situational analysis built on other tools 21 and was developed by WHO/SEARO in the first round of situational analyses in all 11 countries during 2010-13. The tool was piloted for use by government staff in the second round of analyses in eight countries during 2014-15. The situational analysis approach was developed in the WHO South-East Asian region at the request of member states 20 22 but is suitable for use in other low and middle income countries.

Methods

Over two weeks the analysis team visited all major ministry of health departments and agencies responsible for drug supply, selection, use, regulation, drug policy, insurance, and health professional training to understand what each unit did, and what policies were in place. The team also visited healthcare facilities, with the aim of visiting at least 20 facilities, two of each type of public health facility (primary care centres, secondary, and tertiary hospitals) plus private pharmacies in at least two provinces/regions, as selected by the ministry of health.

Data collection and analysis

Data were collected using a predesigned workbook tool 19 (see supplementary data on bmj.com) by a team of four to eight staff nominated by the government, with at least one team member from each of the government departments responsible for drug supply, selection, use, regulation, and policy. Staff at the central level were interviewed using the open questions in the workbook tool about the health system and policies in place. At each health facility, the team reviewed 30 primary care outpatient encounters (using documentation available at the facility, such as prescriptions held in the pharmacy or by the patient, paper slips in the pharmacy, patient records, or outpatient registers). The means for standard indicators of medicines use 21 (including the percentage of patients receiving an antibiotic) were calculated for each facility and each category of facility. Additionally, antibiotic use in 30 cases of upper respiratory tract infection was reviewed, although a lack of records on diagnosis made this difficult in some countries. The percentage of cases with upper respiratory tract infection receiving an antibiotic was calculated for each facility and used to calculate the average for each type of facility. The basis for a diagnosis of upper respiratory tract infection was recorded—for example, runny nose, rhinitis, cough, cold, sore throat, viral acute respiratory infection, acute laryngitis, acute bronchitis, earache, and otitis media. The availability and procurement prices of essential medicines was also checked. The team interviewed health workers (including the health facility manager, a prescriber in the outpatient department, the head of the pharmacy, a dispenser, a nurse, and sometimes other staff) using the open questions in the workbook about management of medicines and implementation of policies, and any problems. Cross-cutting descriptive analysis was done each day and presented by the team at a national workshop at the end of the two weeks. The teams wrote country reports in the workbook tool format, which were published on the WHO/SEARO website after government approval. WHO facilitated and supervised the entire process, including preparation, data collection and analysis, conducting the national workshop, and writing and publishing the country reports. All results presented here were taken from the country reports.19 For indicators of antibiotic use, the averages across all facility types are presented. Where possible (in the later second round situation analyses), we calculated the median, and the 25th and 75th centiles for each country. No further statistical analysis could be done because of the small sample sizes and convenience sampling. For antibiotic management, we focus on policies known to be associated with more appropriate use.15 We present data from all countries to give a regional picture, but we have not made comparisons between countries or over time as the data are insufficient for this purpose.

Findings

National situational analyses were conducted in all 11 countries of the South-East Asia region during 2010-13 and repeated in eight countries during 2014-15. In India, the analysis was done in only two states. In the first round, the data collection tool was being developed by WHO, government staff were less involved, and it was not possible to visit the designated number of health facilities, or collect data on antibiotic use in upper respiratory tract infection in all facilities. In the second round, data collection was done by a full government team using the predesigned workbook tool,19 and it was possible to visit more facilities. The tool was useful for standardised data collection, and it may be further modified based on the experience in countries. Overall, medicines management is under-resourced in terms of funding and human resources in most countries. Partner support from donors, bilateral and multilateral agencies, and non-governmental agencies is generally limited and fragmented. In most countries, drug management, centrally and at facilities, is done manually leading to poor forecasting, quantification and stock management. Only three of 11 countries reported any monitoring of antibiotic use, either by collecting prescribing data or monitoring antibiotic use in hospitals. Drug regulatory authorities are under-resourced and implementation of drug policies about supply, selection, use, and regulation is suboptimal.19 Table 1 summarises antibiotic use in primary care facilities in the public sector, and the presence of policies to promote more appropriate use based on selected indicators from the most recent situational analyses.19 Antibiotic use was high in all countries. Much of it was possibly inappropriate since most cases of upper respiratory tract infection in primary care are viral and do not need an antibiotic.2 4Fig 1 and 2 show the median and centile range of antibiotic use across facilities by country, and also indicate high antibiotic usage. Direct comparison between countries was not possible because the data from the individual surveys were not generalisable, the case mix varied, the capacity of health workers to make accurate diagnoses and their diagnostic terminology varied, and the drugs available were different. However, the lowest antibiotic use for upper respiratory tract infection was in Bhutan and Thailand, both of which had excellent availability of drugs at the facilities.19
Table 1

Antibiotic use in public sector primary care facilities and presence of selected policies in South East Asian countries

Country yearNo of facilities with antibiotic data (No with URTI data)* All outpatientsPatients with URTINational AMR strategyNationalor state rational use of medicines unitNationalor state drug information centreDTCs in most hospitalsNational or state guidelines updated in past 5 yearsYear of latest national or state essential medicines list Public education on antibiotics in past 2 yearsAntibiotics available without prescription
Total No of cases reviewed*Average % (range) given antibiotics across facility typeTotal No of cases reviewed*Average % (range) given antibiotics across facility type
Bangladesh 201410 (6)30031 (19-54)18359 (59-60)NoNoNoNoNo2008NoYes
Bhutan 201513 (12)39041 (33-49)36034 (26-42)NoYes, but smallYesReferral hospitals onlyYes2014NoYes
DPR Korea 201210 (9)30035 (18-51)11065 (58-81)NoNoNoNoYesDraft only in 2012NoYes
Rajasthan, India 201310 (10)30062 (53-67)19894 (81-100)NoYes, in supply unitNoYes, but monitor only EML complianceYes2013NoYes
Karnataka, India 201313† (6)39032† (23-45)16770 (64-78)NoNoYesNoNo2013NoYes
Indonesia 20118† (3‡)24045† (34-55)3072‡2011Yes, but smallYesYesYes2008Yes, in some provincesYes
Maldives 20148 (8)24024 (15-34)21543 (34-48)NoNoNoNoNo2013, but not followedNoYes
Myanmar 201414 (11)42047 (34-54)36087 (73-96)NoNoNoNoYes2010NoYes
Nepal 201410† (7)30044† (39-46)35066 (63-71)2001NoNoReferral hospitals onlyNo2011, but many drugs not suppliedNoYes
Sri Lanka 201510 (8)30056 (45-67)27170 (47-85)NoNoNoStarted in 2015No2014NoYes
Thailand 201514 (13)42012 (11-14)48543 (20-52)2011No, but has committeeNoYesNo, but many protocols2015No, but MOH working group started Yes
East Timor 201516 (15)48043 (39-50)33455 (47-66)NoNoNoNational hospital onlyNo2015, but 2010 version followedOnly in 2016Yes

AMR=antimicrobial resistance, DTC=drug and therapeutic committee, URTI=upper respiratory tract infection.

*30 patient records were reviewed per health facility from which the % receiving an antibiotic was calculated. 30 cases of URTI were reviewed in health facilities which recorded URTI diagnoses from which the % of URTI cases receiving an antibiotic was calculated19

†Includes private outpatient facilities offering some public sector services: two medical colleges in Karnataka, one medical college in Nepal and one military hospital in Indonesia.

‡Analysis of only 30 prescriptions from three primary care facilities.

Antibiotic use in public sector primary care facilities and presence of selected policies in South East Asian countries AMR=antimicrobial resistance, DTC=drug and therapeutic committee, URTI=upper respiratory tract infection. *30 patient records were reviewed per health facility from which the % receiving an antibiotic was calculated. 30 cases of URTI were reviewed in health facilities which recorded URTI diagnoses from which the % of URTI cases receiving an antibiotic was calculated19 †Includes private outpatient facilities offering some public sector services: two medical colleges in Karnataka, one medical college in Nepal and one military hospital in Indonesia. ‡Analysis of only 30 prescriptions from three primary care facilities. Fig 1 Median (25th to 75th centiles) percentage of outpatients prescribed antibiotics across all surveyed public primary care facilities in eight South East Asian countries) Fig 2 Median (25th to 75th centiles) percentage of patients with upper respiratory tract infection prescribed antibiotics across all surveyed public primary care facilities in eight South East Asian countries Implementation of recommended policies to reduce inappropriate use of antibiotics14 15 was poor.19 Antibiotics were available over the counter without prescription in all countries, even though this is illegal in all countries except Thailand and East Timor. Qualitative information on possible causes of inappropriate antibiotic use was collected by interviewing healthcare workers in all countries. Between three and 10 health workers from each of 200 facilities (depending on size) were interviewed. Many health workers were aware that antibiotics were misused and cited various reasons, including patient demand, poor drug supply, and lack of diagnostic facilities, training, appropriate information, and time. Box 2 gives some examples of the views of the health workers taken from the country reports.19 “How can I make a proper diagnosis in one minute?” (Doctor in Bangladesh) “According to STGs [standard treatment guidelines] for fever, coughs and colds, we should give paracetamol for a few days and only give antibiotics if there is no response, but I like to give the complete treatment (ie, antibiotics) from the start.” (Doctor in Sri Lanka) “For children under 5 years with pneumonia I must give amoxicillin according to the IMCI [Integrated Management of Childhood Illness] guidelines. Since we are short of amoxicillin and have short-dated chloramphenicol syrup, I am prescribing chloramphenicol syrup to children of more than 5 years with pneumonia in order to use up the stock.” (Health post in-charge (senior auxiliary health worker who is a paramedical staff of two to three years training) in Nepal) “We have a lot of soon-to-expire erythromycin so we are pushing it to the dispensary and we will finish it in a few days.” (Pharmacy technician in East Timor) “I do not like to go to the hospital because of the long wait and the difficulty to see the correct doctor.” (Pharmacy customer in Bhutan) “We urgently need national standard treatment guidelines to ensure that drugs are used properly and not wasted.” (Senior policy maker in Myanmar) “We have to give antibiotics like azithromycin and cefixime because the patients have already been prescribed the simpler antibiotics by unqualified practitioners.” (Medical officer in Rajasthan, India) Antibiotic use was heavily influenced by availability of drugs, staffing policies, and implementation of regulations, as well as the knowledge, beliefs, and qualifications of the health workers. Private pharmacy owners and dispensers in many countries stated that if they did not sell antibiotics without prescription, they would lose business because the patients would simply go elsewhere. These views may not be representative of practice in the entire country or region, but previous studies have reported all these causes.23 The process ended with national workshops to develop recommendations based on the findings with participation from government officials, health workers, and partner organisations. Recommendations were made in all countries 19 to establish and strengthen hospital drug and therapeutic committees; undertake public education on antibiotic use; enforce prescription only availability for newer antibiotics; and establish a government unit with direct responsibility for monitoring use of medicines and coordinating implementation of policies to encourage rational use. In eight countries where two situational analyses were done, the action taken on the recommendations made in the first situational analysis was assessed. Table 2 summarises antibiotic use in public sector primary care in these eight countries in the first and second analyses, and the measures that were taken to improve appropriate use.
Table 2

Antibiotic use in public sector primary care facilities and policy changes in eight countries for which a situational analysis was done twice during 2010-1519

CountryNo of public facilities, patient encounters (No with URTI data)Average % (range) of outpatients given antibiotics across facility typeAverage % (range) of patients with URTI given antibiotics across facility typeNew policies implemented between 2010-12 and 2014-15
2010-122014-152010-12†2014-15†2010-12†2014-15†
Bangladesh4, 120 (0)10, 300 (6, 183)48 (34-74)31 (19-54)59 (59-60)None. Variable drug availability in terms of supply and type
Bhutan8, 240 (0)13, 390 (12, 360)33 (31-34)41 (33-49)34 (26-42)Some monitoring and continuing medical education, updated essential medicines list and standard treatment guidelines, and good drug availability
Maldives5, 150 (0)8, 240 (8, 215)38 (35-43)24 (15-34)43 (34-48)None. Decreased drug availability
Myanmar10, 300 (8, 90)14, 420 (11, 360)38 (27-56)47 (34-54)83 (72-100)87 (73-96)None. Increased drug availability
Nepal13, 390 (9, 110)10, 300 (7, 350)47 (21-54)44* (39-46)73 (72-74)66 (63-71)Non-governmental organisation rational use of medicine project in a few districts. Variable drug availability
Sri Lanka6, 180 (0)10,300 (8, 271)49 (22-66)56 (45-67)70 (47-85)Drug and therapeutic committees started in 2015. Variable drug availability
Thailand9, 270 (6, 73)14, 420 (13, 485)30 (23-45)12 (11-14)57 (54-62)43 (20-52)Monitoring use, updated essential medicines list, drug and therapeutic committees, and antibiotic smart use and PLEASE projects†¶
East Timor10, 300 (8, 153)16, 480 (15, 334)50 (42-75)43 (39-50)77 (69-88)55 (47-66)None. Decreased drug availability

URTI=upper respiratory tract infection.

*Includes one medical college in Nepal offering some public services.

†Antibiotic smart use project, started in 2007, consists of multifaceted interventions at the individual, organisational, network, and policy levels aimed at changing behaviour, maintaining the changes, and scaling up the project. Activities vary across institutions. ¶PLEASE project, started in 2014 in 71 hospitals. It consists of: pharmacy and therapeutics committee (P), labelling and leaflet (L), essential tools for rational use of medicines (E), awareness of rational use among prescribers and patients (A), special population care (S), and ethics in promotion (E).

Antibiotic use in public sector primary care facilities and policy changes in eight countries for which a situational analysis was done twice during 2010-1519 URTI=upper respiratory tract infection. *Includes one medical college in Nepal offering some public services. †Antibiotic smart use project, started in 2007, consists of multifaceted interventions at the individual, organisational, network, and policy levels aimed at changing behaviour, maintaining the changes, and scaling up the project. Activities vary across institutions. ¶PLEASE project, started in 2014 in 71 hospitals. It consists of: pharmacy and therapeutics committee (P), labelling and leaflet (L), essential tools for rational use of medicines (E), awareness of rational use among prescribers and patients (A), special population care (S), and ethics in promotion (E). Antibiotic use in primary care remained high in all countries, apart from in Thailand where it appeared to have decreased substantially. Thailand was also the only country to report specific nationwide actions to reduce inappropriate antibiotic use.24 These included monitoring use, a project to improve prescribing behaviour25 using multifaceted behaviour change interventions, strengthening hospital drug and therapeutic committees, and regularly updating its essential medicines list. However, the figures should be interpreted with caution. Direct comparison between the two periods is not possible because of the small sample sizes and the selection of different facilities. Furthermore, some countries reported changes in the availability and types of essential medicines which could have affected measurement of antibiotic use between the two periods.

Benefits and limitations of country situational analyses

The situational analyses enabled the rapid collection of data sufficient to show worryingly high use of antibiotics in primary care, and poor implementation of policies to promote more appropriate use.15 Although the data are limited, and not generalisable to the national situation, they have identified serious problems, and provided evidence to advocate for feasible solutions. The data highlight to governments ongoing antibiotic misuse in public primary care, possible reasons for misuse, and the urgent need to implement policies to encourage more appropriate use.19 The analyses have also allowed some monitoring of progress. Since the assessment is completed within two weeks, it is cheap and flexible. Involvement of government staff in data collection helps build their capacity to assess antibiotic use and policy implementation, and increases the likelihood of government follow up. It remains to be seen if greater government involvement guarantees action. Data collection in the private and hospital sectors was too limited for useful regional analysis. A substantial proportion of antibiotic use occurs in primary care, however, and we expect private sector antibiotic prescribing to be similar to that in the public sector.2 3 The quality of the data may have been affected by time and resource constraints. However, error was minimised by WHO staff supervising all data collection. Furthermore, similar results about antibiotic management in South East Asia have been reported elsewhere.1 2 3 4 5 6 7 10 11 12 13

Developing political will and an enabling environment

The situational analyses would not have been possible without political will. Developing a mandate for action took six years, and involved two regional meetings with experts and senior government officials to finalise the process.26 27 The recommendations of each meeting were incorporated into two WHO regional resolutions adopted by the governments of member states of the South-East Asia region.20 22 Even with a mandate, many government officials feared that they might be blamed for any negative findings, and this may have led to a reluctance to collect and share data on antibiotic management. However, constant reassurance by WHO that the purpose of the situation analyses was not to find fault but to identify weaknesses in the healthcare system, and possible solutions, reduced staff fears, and resulted in free and frank discussions in the national workshops .19 In conclusion, inappropriate use of antibiotics is high, and implementation of policies to encourage more appropriate use is poor in many South-East Asian countries. We recommend that countries take the following actions: Undertake regular situational analyses to monitor antibiotic use, and policy implementation as already mandated by WHO member states20 Develop a national coordinating mechanism, and establish a government unit to regularly monitor the use of medicines and antibiotics, and policy implementation Strengthen hospital drug and therapeutics committees, and update and implement national standard treatment guidelines by training health staff, monitoring the use of medicines, and ensuring that the drug supply matches what is recommended in the guidelines Invest in public education, and regulate over-the-counter availability of newer antibiotics. While the member state resolutions have enabled the country situational analyses on medicines management to be done, constant follow up by governments, WHO and partners, and appropriate investment will be needed to make progress. Country situational analyses provide rapid assessment of antibiotic use and policies, particularly where infrastructure for routine monitoring is lacking, so help to build political will and government capacity to take action to improve the appropriate use of antibiotics South East Asian countries have high antibiotic use, and poor implementation of policies to encourage appropriate use Measures such as a dedicated government unit for antimicrobial stewardship, a national strategy to contain antimicrobial resistance, updated standard treatment guidelines, hospital drug and therapeutic committees, public education, and restriction of newer antibiotics being available without prescription must be implemented
  12 in total

1.  Bacterial resistance: origins, epidemiology, and impact.

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

Review 2.  Improving antibiotic use in low-income countries: an overview of evidence on determinants.

Authors:  Aryanti Radyowijati; Hilbrand Haak
Journal:  Soc Sci Med       Date:  2003-08       Impact factor: 4.634

3.  Antibiotic prescribing practice for acute, uncomplicated respiratory tract infections in primary care settings in New Delhi, India.

Authors:  Anita Kotwani; Kathleen Holloway
Journal:  Trop Med Int Health       Date:  2014-04-22       Impact factor: 2.622

4.  Antibiotics Smart Use: a workable model for promoting the rational use of medicines in Thailand.

Authors:  Nithima Sumpradit; Pisonthi Chongtrakul; Kunyada Anuwong; Somying Pumtong; Kedsenee Kongsomboon; Parichart Butdeemee; Jurairat Khonglormyati; Santi Chomyong; Parnuchote Tongyoung; Suraphol Losiriwat; Piyanooch Seesuk; Pongthep Suwanwaree; Viroj Tangcharoensathien
Journal:  Bull World Health Organ       Date:  2012-09-27       Impact factor: 9.408

5.  Antibiotic-prescribing practices of primary care prescribers for acute diarrhea in New Delhi, India.

Authors:  Anita Kotwani; Ranjit Roy Chaudhury; Kathleen Holloway
Journal:  Value Health       Date:  2012 Jan-Feb       Impact factor: 5.725

Review 6.  Combating inappropriate use of medicines.

Authors:  Kathleen Anne Holloway
Journal:  Expert Rev Clin Pharmacol       Date:  2011-05       Impact factor: 5.045

Review 7.  Prescribing for acute childhood infections in developing and transitional countries, 1990-2009.

Authors:  Kathleen Anne Holloway; Verica Ivanovska; Anita Katharina Wagner; Catherine Vialle-Valentin; Dennis Ross-Degnan
Journal:  Paediatr Int Child Health       Date:  2014-02-06       Impact factor: 1.990

Review 8.  Antimicrobial resistance determinants and future control.

Authors:  Stephan Harbarth; Matthew H Samore
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

9.  New chapter in tackling antimicrobial resistance in Thailand.

Authors:  Nithima Sumpradit; Suriya Wongkongkathep; Sitanan Poonpolsup; Noppavan Janejai; Wantana Paveenkittiporn; Phairam Boonyarit; Sasi Jaroenpoj; Niyada Kiatying-Angsulee; Wantanee Kalpravidh; Angkana Sommanustweechai; Viroj Tangcharoensathien
Journal:  BMJ       Date:  2017-09-05

10.  WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys.

Authors:  Kathleen Anne Holloway; David Henry
Journal:  PLoS Med       Date:  2014-09-16       Impact factor: 11.069

View more
  35 in total

1.  Antimicrobial Resistance Research Collaborations in Asia: Challenges and Opportunities to Equitable Partnerships.

Authors:  Pami Shrestha; Shiying He; Helena Legido-Quigley
Journal:  Antibiotics (Basel)       Date:  2022-06-01

2.  Why do people purchase antibiotics over-the-counter? A qualitative study with patients, clinicians and dispensers in central, eastern and western Nepal.

Authors:  Bipin Adhikari; Sunil Pokharel; Shristi Raut; Janak Adhikari; Suman Thapa; Kumar Paudel; Narayan G C; Sandesh Neupane; Sanjeev Raj Neupane; Rakesh Yadav; Sirapa Shrestha; Komal Raj Rijal; Sujan B Marahatta; Phaik Yeong Cheah; Christopher Pell
Journal:  BMJ Glob Health       Date:  2021-05

3.  Risk assessment for antibiotic resistance in South East Asia.

Authors:  Fanny Chereau; Lulla Opatowski; Mathieu Tourdjman; Sirenda Vong
Journal:  BMJ       Date:  2017-09-05

4.  The social role of C-reactive protein point-of-care testing to guide antibiotic prescription in Northern Thailand.

Authors:  Marco J Haenssgen; Nutcha Charoenboon; Thomas Althaus; Rachel C Greer; Daranee Intralawan; Yoel Lubell
Journal:  Soc Sci Med       Date:  2018-02-23       Impact factor: 4.634

5.  Antibiotics and activity spaces: protocol of an exploratory study of behaviour, marginalisation and knowledge diffusion.

Authors:  Marco J Haenssgen; Nutcha Charoenboon; Giacomo Zanello; Mayfong Mayxay; Felix Reed-Tsochas; Caroline O H Jones; Romyen Kosaikanont; Pollavat Praphattong; Pathompong Manohan; Yoel Lubell; Paul N Newton; Sommay Keomany; Heiman F L Wertheim; Jeffrey Lienert; Thipphaphone Xayavong; Penporn Warapikuptanun; Yuzana Khine Zaw; Patchapoom U-Thong; Patipat Benjaroon; Narinnira Sangkham; Kanokporn Wibunjak; Poowadon Chai-In; Sirirat Chailert; Patthanan Thavethanutthanawin; Krittanon Promsutt; Amphayvone Thepkhamkong; Nicksan Sithongdeng; Maipheth Keovilayvanh; Nid Khamsoukthavong; Phaengnitta Phanthasomchit; Chanthasone Phanthavong; Somsanith Boualaiseng; Souksakhone Vongsavang; Rachel C Greer; Thomas Althaus; Supalert Nedsuwan; Daranee Intralawan; Tri Wangrangsimakul; Direk Limmathurotsakul; Proochista Ariana
Journal:  BMJ Glob Health       Date:  2018-03-28

6.  Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial.

Authors:  Thomas Althaus; Rachel C Greer; Myo Maung Maung Swe; Joshua Cohen; Ni Ni Tun; James Heaton; Supalert Nedsuwan; Daranee Intralawan; Nithima Sumpradit; Sabine Dittrich; Zoë Doran; Naomi Waithira; Hlaing Myat Thu; Han Win; Janjira Thaipadungpanit; Prapaporn Srilohasin; Mavuto Mukaka; Pieter W Smit; Ern Nutcha Charoenboon; Marco Johannes Haenssgen; Tri Wangrangsimakul; Stuart Blacksell; Direk Limmathurotsakul; Nicholas Day; Frank Smithuis; Yoel Lubell
Journal:  Lancet Glob Health       Date:  2019-01       Impact factor: 26.763

7.  Promoting quality use of medicines in South-East Asia: reports from country situational analyses.

Authors:  Kathleen Anne Holloway; Anita Kotwani; Gitanjali Batmanabane; Budiono Santoso; Sauwakon Ratanawijitrasin; David Henry
Journal:  BMC Health Serv Res       Date:  2018-07-05       Impact factor: 2.655

Review 8.  Antimicrobial resistance in the environment: The Indian scenario.

Authors:  Neelam Taneja; Megha Sharma
Journal:  Indian J Med Res       Date:  2019-02       Impact factor: 2.375

Review 9.  Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications.

Authors:  Christy Manyi-Loh; Sampson Mamphweli; Edson Meyer; Anthony Okoh
Journal:  Molecules       Date:  2018-03-30       Impact factor: 4.411

10.  A Comparison of Patients' Local Conceptions of Illness and Medicines in the Context of C-Reactive Protein Biomarker Testing in Chiang Rai and Yangon.

Authors:  Yuzana Khine Zaw; Nutcha Charoenboon; Marco J Haenssgen; Yoel Lubell
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.